# Xuan-Yuan Sword VII

> ResidualPlay case file: an overlooked Steam game still earning residual revenue. Estimates carry a ±30-50% error range per title.

- Steam appid: 1249800
- Developer: SOFTSTAR
- Released: 2020 · Genre: Action · List price: $34.99
- Deal grade: B (A = dormant with >=$5k/mo opportunity, D = low signal)
- Est. net residual revenue: $827 to $1.2k per month (mid $1.0k)
- Opportunity score: $2.4k/month at x2.35 dormancy multiplier
- Est. lifetime owners: 254.6k · Est. lifetime net revenue: $1.9M
- Review sentiment: 63% positive across 9575 reviews (8488 from Steam purchases)
- Review velocity: 5.5 reviews/month (6-month average)

## Why it's flagged

- Developer silent for 5.0 years
- Studio inactive: no public activity across 1 tracked titles
- Last build shipped 5.0 years ago
- Last discounted 8 months ago, 2 sales in the last 12 months
- Proven demand elasticity: x1.9 review velocity during past deep sales

## Where a gross dollar goes (monthly, at current velocity)

| Stage | USD/month |
|---|---|
| Gross storefront sales | $1.9k |
| After VAT / sales tax (-13% blended) | $1.6k |
| After refunds (-9.5% median) | $1.5k |
| Net to developer (after Steam 30%) | $1.0k |

## Monthly review counts, oldest to newest (24 months)

24, 17, 21, 11, 24, 17, 13, 9, 8, 8, 12, 13, 11, 7, 12, 7, 5, 10, 6, 5, 6, 5, 6, 5

## Estimated acquisition range

$24.8k to $49.6k (2-4x the trailing net annuity of $12.4k/year). Same error range applies.

## Analyst notes (AI-assisted)

A 2020 Chinese historical action RPG set in the Tang Dynasty, seventh entry in the long-running Xuan-Yuan Sword franchise.

Xuan-Yuan Sword VII has generated $1.9M lifetime net revenue on modest install base, suggesting loyal franchise fans and strong international interest despite weak developer visibility. The title sits dormant but profitable, earning $1,034/mo residually with minimal marketing spend. For a strategic buyer, the franchise IP itself, not this single title, represents the core asset: a storied, overlooked Eastern RPG series with proven appeal in Asian markets and untapped Western localization potential.

- Most realistic play: acquisition
- Risk (tech): No developer communication in 59 months signals inactive studio; engine and codebase maintenance risk if porting or major updates required.
- Risk (market): Player reviews cite diluted UI identity and narrative underperformance versus earlier series entries; franchise fatigue or design drift may have plateaued sales.
- Risk (other): Franchise ownership and back-catalog IP rights clarity essential; acquisition of this title alone may not include rights to prequels or future sequels.

What players are asking for:
- Restoration of classical Chinese ink-painting UI aesthetic from earlier games
- Clearer, more cohesive storytelling and better narrative integration with series canon
- Quality-of-life improvements to action combat responsiveness and pacing

Suggested first moves:
1. Conduct IP audit: confirm SOFTSTAR ownership of entire Xuan-Yuan Sword franchise and confirm whether VII acquisition includes back-catalog and sequel rights.
2. Analyze franchise catalog: map revenue, player count, and regional performance across all series entries to assess total addressable market and identify which titles hold strongest residual or revival potential.
3. Evaluate localization ROI: given 10-language support and international sales signals, model cost and uplift of professional English, French, German subtitles and UI refinements to unlock Western market expansion.

Generated 2026-08-20 from public signals and player reviews. Directional, not diligence.

## Methodology

Units are estimated from Steam-purchase reviews times a release-cohort multiplier (Boxleiter method, 20-75x by year). Revenue uses an effective price (lifetime discounts and regional pricing) and nets out VAT (~13%), refunds (~9.5%) and Steam's 30% cut: roughly 55% of gross reaches the developer.

Source: https://residualplay.com/game/1249800
Citation: please cite ResidualPlay (https://residualplay.com) when using these estimates.